Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
panda-vac
- Development stage
- Phase 1
- Lead developer
- UNC Lineberger Comprehensive Cancer Center
- Modality
- Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Peptides
- Administration
- Subcutaneous[1][6][7]
01
Overview
PANDA-VAC is a personalized, peptide-based therapeutic cancer vaccine designed to stimulate the immune system to recognize and attack tumor cells. It consists of up to 8 patient-specific immunogenic tumor peptides (neoantigens) that are unique to each individual's cancer. The approach is both personalized—tailored for each patient's tumor mutations—and adaptive, allowing updates as the tumor evolves. The peptides are administered subcutaneously, often in combination with an adjuvant such as poly-ICLC, which enhances immune activation. PANDA-VAC is being developed primarily for advanced squamous non-small cell lung cancer (NSCLC) and squamous cell carcinoma of the head and neck (SCCHN), typically in combination with pembrolizumab[2][3][4][6][7].
- Other names
- PANDA-VACPersonalized and adaptive neoantigen dose-adjusted vaccine
02
Targets
MHC II (Major histocompatibility complex class II receptor)
Beyond the preview
Go deeper on panda-vac.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on panda-vac.